Advancing Rare Disease Therapies
Rare disease programs carry urgent patient stakes and uniquely complex development demands. SK pharmteco helps innovators address these realities early and effectively, supporting the advancement of high-impact therapies from complex science toward reliable supply.
With robust and responsive viral vector platforms and flexible CDMO models, SK pharmteco supports rare disease therapy development from early work through clinical and commercial manufacturing.
Advancing rare disease therapies through partnerships
By combining NIH research, Axle Informatics coordination, and SK pharmteco viral vector manufacturing expertise, we manufactured lentiviral vector drug substance intended for future ex vivo transduction of patients’ CD34+ hematopoietic stem cells and managed batch-release testing, with most analytical assays performed in-house at its specialized laboratories. These types of collaborations are helping create a practical path for promising rare disease programs to move closer to the clinic and, ultimately, to the patients who need them.
Rare disease programs often face unique challenges, from addressing high unmet need patient populations to overcoming complex development hurdles and funding constraints. Through the Rare Disease Advancement Initiative, SK pharmteco helps high-impact programs move forward with practical CDMO support, thoughtful commercial flexibility, and manufacturing strategies designed for long-term scalability.
Expertise is available across AAV, LVV, and adenoviral vector platforms and SK pharmteco can support rare disease developers with the development and manufacturing capabilities needed to advance promising therapies from early development through commercial supply.
SK pharmteco’s collaboration with Orphan Therapeutics Accelerator demonstrates the strength of its rare disease CDMO model through flexible partnership, specialized technical expertise, and reliable execution designed to advance complex therapies from development to clinical and commercial milestones.
With a “no project too small” mindset, SK pharmteco supports rare disease innovators at critical inflection points, from early process work and clinical manufacturing to scale-up planning and future supply readiness. The goal is simple: help accelerate the delivery of life-changing therapies to the patients and communities who need them most.
Viral Vector Program Support
Rare disease gene therapy programs require platforms that can support precision, speed, and scale. SK pharmteco’s viral vector capabilities include AAV, lentiviral, and adenoviral platforms designed to help developers move from early development through clinical and commercial manufacturing.
For rare disease programs pursuing expedited regulatory pathways, speed must be matched by strong CMC execution. SK pharmteco’s integrated CDMO services are designed to help developers move quickly and confidently, supporting process development, plasmid and cell line activities, drug substance and drug product manufacturing, scalable production strategies, phase-appropriate analytical services, and regulatory readiness.
With operations across North America and Europe, SK pharmteco helps rare disease sponsors create adaptable manufacturing pathways that can support near-term clinical milestones while planning for long-term supply and patient access.
This includes critical CMC activities such as placebo batch manufacturing for double-blind clinical controls, successful manufacture and release of Master and Working Cell Banks, robust stability studies, and validated analytical methods. Together, these capabilities help establish the manufacturing and analytical foundation needed to progress efficiently from Phase I/II development to pivotal Phase III studies.
For sponsors pursuing Orphan Drug Designation, Fast Track, Breakthrough Therapy, RMAT, Accelerated Approval, or Priority Review, this ability to move with urgency while maintaining manufacturing control, reliable analytical data, and regulatory-ready documentation is essential to helping bring therapies to patients faster.
How SK pharmteco Supports Sponsors Through Rare Disease Regulatory Pathways
For rare disease programs, speed matters, but so do quality, control, and regulatory readiness. As a Rare Disease CDMO, SK pharmteco helps sponsors build the CMC foundation needed to support expedited development pathways, helping ensure therapies are manufacturable, testable, stable, scalable, and ready to release.
Resources
Contact us
We’re committed to supporting your development and manufacturing needs. Complete the form and someone from SK pharmteco will be in touch shortly.